- Molecular NameGabapentin
- Synonymgabapentin; Gabapentin GR; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentino [Spanish]; Gabapentinum [INN-Latin]; Gabapetin
- Weight157.213
- Drugbank_IDDB00996
- ACS_NO60142-96-3
- Show 3D model
- LogP (experiment)-1.1
- LogP (predicted, AB/LogP v2.0)-1.76
- pka3.68, 10.7
- LogD (pH=7, predicted)-1.76
- Solubility (experiment)101 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.91
- LogSw (predicted, AB/LogsW2.0)95.87
- Sw (mg/ml) (predicted, ACD/Labs)19.5
- No.of HBond Donors3
- No.of HBond Acceptors3
- No.of Rotatable Bonds2
- TPSA63.32
- StatusFDA approved
- AdministrationN/A
- PharmacologyA GABA analogue. It was originally developed for the treatment of epilepsy, and currently, gabapentin is widely used to relieve pain, especially neuropathic pain.
- Absorption_value57.0
- Absorption (description)Gabapentin is well absorbed after oral administration
- Caco_2N/A
- Bioavailability60.0
- Protein binding3.0
- Volume of distribution (VD)0.8 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Drug penetrates red blood cells. Extravascular distribution.
- MetabollsmNot metabolised within the body.
- Half life6.5 h
- Excretion80% of a single dose is excreted unchanged in urine and the rest in faeces. It is widely distributed throughout the body and easily crosses the blood–brain barrier.
- Urinary Excretion66
- Clerance1.6 ml/min/kg
- ToxicityUp to 49 g of gabapentin has been reported in a single overdose with drowsiness, mild diarrhoea, dizziness, double vision, slurred speech and lethargy as symptoms. Full recovery was made.
- LD50 (rat)N/A
- LD50 (mouse)N/A